BREAKING NEWS
Gene Therapy Found to Be Promising for β-Thalassemia
 

For patients with severe β-thalassemia, the need for red-cell transfusions can be reduced or eliminated by transducing cells with the LentiGlobin BB305 vector, according to a study published the New England Journal of Medicine. “Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long-term red-cell transfusions in 22 patients with severe β-thalassemia without serious adverse events related to the drug product,” the authors write.


Thu, 19 Apr 2018 BREAKING NEWS
AAN: Erenumab Shows Promise for Hard-to-Treat Migraine
 

For patients with episodic migraine who have failed prior preventive migraine treatments (PMTs), erenumab is associated with an increase in the proportion of patients achieving a ≥50 percent reduction in mean monthly migraine days (MMDs), according to a study presented at the annual meeting of the American Academy of Neurology, in Los Angeles. “Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief,” author Uwe Reuter, M.D., said.


Thu, 19 Apr 2018 BREAKING NEWS
Marital Status Tied to Earlier Presentation of Melanoma
 

For patients with localized melanoma, marital status is associated with earlier T stage presentation, according to a study published in JAMA Dermatology. Researchers conducted a retrospective study using the Surveillance, Epidemiology, and End Results database of 18 population-based registered cancer institutes and found that 45.7% of married patients presented with T1a disease, compared with 43.0, 39.0, and 32.2% of never married, divorced, and widowed patients. Conversely, 9.4 and 3.3% of widowed and married patients, respectively, presented with T4b disease.


Thu, 19 Apr 2018 BREAKING NEWS
Triple Therapy Tied to Reduced Rate of COPD Exacerbations
 

For patients with chronic obstructive pulmonary disease (COPD), triple therapy is associated with a reduced rate of exacerbations, research in the New England Journal of Medicine suggests. Researchers conducted a randomized trial involving 10,355 patients with COPD and found the rate of moderate or severe exacerbations was 0.91 annually in the triple-therapy group, compared with 1.07 in the fluticasone furoate-vilanterol group (rate ratio with triple therapy, 0.85) and 1.21 in the umeclidinium-vilanterol group (rate ratio with triple therapy, 0.75).


Thu, 19 Apr 2018 BREAKING NEWS
Calcium Channel Blockers May Up Pancreatic Cancer Risk in Women
 

Use of short-acting calcium channel blockers (CCBs) is associated with increased risk of pancreatic cancer in postmenopausal women, according to a prospective study of 145,553 postmenopausal women presented at the annual meeting of the American Association for Cancer Research, in Chicago. The hazard ratio for pancreatic cancer was 1.48 for long-term users of CCBs (3+ years) versus never users. “We were… surprised by the unexpected increased risk of pancreatic cancer observed among users of short-acting CCBs,” the authors said.


Wed, 18 Apr 2018 BREAKING NEWS
Caffeine Does Not Appear to Be Linked to Risk of Arrhythmia
 

Regular intake of coffee and tea doesn't appear to be associated with the risk of arrhythmia, a review in JACC: Clinical Electrophysiology suggests. Researchers found that clinical studies haven't shown deleterious effects of caffeine on atrial and ventricular electrophysiologic properties. “Although there is no clearly defined threshold for caffeine harm, a regular intake of up to 300 mg/day appears to be safe and may even be protective against heart rhythm disorders,” the authors write.


Wed, 18 Apr 2018 BREAKING NEWS